+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating IM-101 in adults with generalized myasthenia gravis gMG and ocular myasthenia gravis oMG, focusing on those with acetylcholine receptor AChR antibody-positive and AChR antibody-negative forms. The goal is to assess the safety, tolerability, how the drug moves through and affects the body, and the potential effectiveness of IM-101. This Phase 1b2 trial is sponsored by ImmunAbs Inc. and includes multiple study parts to explore these aspects thoroughly. Participants will receive IM-101 or a placebo through intravenous infusions. In Part A, participants get a loading dose on Day 1 and Day 15, followed by a maintenance dose on Day 29, with doses escalating across cohorts. In Part B, dosing includes loading doses on Day 1 and Day 15 and maintenance doses on Days 29, 57, and 85. Some may receive additional doses depending on decisions by an independent data monitoring committee. The study uses randomized, double-blind assignments to compare different dose levels and placebo effects. During the study, participants will be monitored for side effects and safety up to about 99 days in Part A and 169 days in Part B. Researchers will assess the impact of treatment on daily living activities and specific myasthenia gravis severity scores at baseline and Week 16. Safety assessments include tracking adverse events, serious adverse events, and events leading to discontinuation. Participants will undergo regular evaluations to measure the pharmacokinetics and pharmacodynamics of IM-101, with follow-up visits scheduled according to the dosing timeline.

Age: 18Years - 74YearsAll GendersPhase 1Phase 2
25 locations
S

Actively Recruiting

Researchers are studying LTI-03, an experimental inhaled medication, for the treatment of Idiopathic Pulmonary Fibrosis IPF, a progressive and fatal lung disease that causes scarring and loss of lung function. The study aims to assess the safety, side effects, and potential benefits of LTI-03 in improving lung scarring and symptoms in patients diagnosed with IPF within the last five years. Participants on stable doses of certain approved IPF medications may join. The study is a Phase 2, randomized, double-blind, placebo-controlled trial comparing LTI-03 to a placebo. Participants will inhale LTI-03 or placebo capsules twice daily using a dry powder inhaler. The trial includes a 28-day screening period, a 24-week treatment period, and a 4-week follow-up. Lung scans will be done at the start and end of treatment, with several clinic visits throughout the study. Participants will attend up to nine clinic visits where lung function tests, blood samples for safety and disease markers, and questionnaires about IPF symptoms will be conducted. Safety will be monitored through physical exams, vital signs, heart tests, and tracking side effects and medication changes. The main outcome will measure safety by recording treatment-related side effects over 24 weeks, while lung function and lung scarring changes will also be evaluated.

Age: 40Years +All GendersPhase 2
48 locations
R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.

Age: 18Years - 60YearsAll GendersPhase 3
83 locations
E

Actively Recruiting

Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.

Age: 18Years - 60YearsAll GendersPhase 3
90 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of Afimkibart also known as RO7790121 in adults with moderate to severe rheumatoid arthritis RA who have not responded well or cannot tolerate tumor necrosis factor TNF andor Janus kinase JAK inhibitors. This Phase II, multicenter, randomized, double-blind, placebo-controlled study aims to compare Afimkibart with placebo in this group to better understand its impact on disease activity. Participants will receive either Afimkibart or a placebo through subcutaneous under the skin injections. The study includes two experimental groups receiving Afimkibart and one placebo group, all administered by injection. Treatment and assessments occur over several weeks, with key evaluations at Week 14 and Week 24 to measure changes in disease activity and response. During the study, participants will undergo various assessments including joint counts, patient and physician global assessments, laboratory tests for inflammation markers, and questionnaires on health status and pain. The main outcome is the change in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein DAS28-CRP at Week 14. Safety will be monitored throughout the trial up to Week 38, including tracking adverse events and immune responses to the drug. Participants can expect regular visits for injections and evaluations during this period.

Age: 18Years +All GendersPhase 2
65 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of ruxolitinib cream in children aged 6 to under 12 years old who have nonsegmental vitiligo. This phase 3 study aims to understand how well ruxolitinib cream works to improve skin depigmentation in this young population. The study compares two strengths of ruxolitinib cream against a placebo cream, with participants randomly assigned to one of the groups. Participants apply either 0.75% or 1.5% ruxolitinib cream, or a matching placebo cream, as a thin layer on the affected skin areas twice daily. The treatment lasts for 24 weeks, with the primary goal of measuring improvement in facial vitiligo area. The study also monitors other outcomes such as body vitiligo improvement, patient satisfaction, and possible side effects for up to 52 weeks. During the study, participants will be regularly assessed for changes in their vitiligo using standardized scoring indexes and questionnaires that measure the impact on quality of life. Blood samples will be taken at several points to study the drugs levels in the body. Safety is closely monitored, and participants are followed through a final safety visit. Overall participation can last up to around one year, including treatment and follow-up periods.

Age: 6Years - 11YearsAll GendersPhase 3
78 locations

1-10 of 21

1